


## Data Sheet

<b>Product Name:</b>	PP121
<b>Cat. No.:</b>	CS-0087
<b>CAS No.:</b>	1092788-83-4
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>17</sub> N <sub>7</sub>
<b>Molecular Weight:</b>	319.36
<b>Target:</b>	Apoptosis; mTOR; PDGFR; Src; VEGFR
<b>Pathway:</b>	Apoptosis; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK
<b>Solubility:</b>	DMSO : 20 mg/mL (62.63 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

PP121 is a multi-targeted kinase inhibitor with **IC<sub>50</sub>s** of 10, 60, 12, 14, 2 nM for **mTOR, DNK-PK, VEGFR2, Src, PDGFR**, respectively. IC<sub>50</sub> & Target: IC<sub>50</sub>: 10 nM (mTOR), 60 nM (DNK-PK), 12 nM (VEGFR2), 14 nM (Src), 2 nM (PDGFR)<sup>[1]</sup> **In Vitro:** PP121 blocks the PI3K pathway by direct inhibition of PI3K/mTOR in two glioblastoma cell lines, U87 and LN229. PP121 potently inhibits the proliferation of a diverse panel of tumor cell lines containing mutations in the PI3-K pathway components PIK3CA, PTEN, or RAS. PP121 induces a G<sub>0</sub>G<sub>1</sub> arrest in most tumor cells. PP121 directly inhibits Src in cells and reverses its biochemical and morphological effects. PP121 potently inhibits the Ret kinase domain in vitro (IC<sub>50</sub><1 nM). PP121 potently blocks VEGF stimulated activation of the PI3-K and MAPK pathways. PP121 inhibits VEGFR2 autophosphorylation at low nanomolar concentrations, confirming that this molecule directly targets VEGFR2 in cells. PP121 inhibits Bcr-Abl induced tyrosine phosphorylation in K562 cells as well as BaF3 cells that express Bcr-Abl<sup>[1]</sup>. **In Vivo:** Oral administration of PP121 remarkably inhibits Eca-109 xenograft growth. Mice body weights are not significantly affected by PP121 or the vehicle treatment. PP121 oral administration dramatically inhibits activations of Akt-mTOR and NFκB in xenograft tumors. p-Akt Ser 473 and p-IKκa/b are both inhibited by PP121 administration<sup>[2]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

**Kinase Assay:** <sup>[1]</sup>Purified kinase domains are incubated with inhibitors (PP121) at 2- or 4-fold dilutions over a concentration range of 50- 0.001 μM or with vehicle (0.1% DMSO) in the presence of 10 μM ATP, 2.5 μCi of γ- <sup>32</sup>P-ATP and substrate. Reactions are terminated by spotting onto nitrocellulose or phosphocellulose membranes, depending on the substrate; this membrane is then washed 5-6 times to remove unbound radioactivity and dried. Transferred radioactivity is quantitated by phosphorimaging and IC<sub>50</sub> values are calculated by fitting the data to a sigmoidal doseresponse using Prism software<sup>[1]</sup>. **Cell Assay:** PP121 is prepared in 0.1% DMSO<sup>[1]</sup>. Cells grown in 96-well plates are treated with PP121 at 4-fold dilutions (10 μM - 0.040 μM) or vehicle (0.1% DMSO). After 72 h cells are exposed to Resazurin sodium salt (22 μM) and fluorescence is quantified. IC<sub>50</sub> values are calculated. For proliferation assays involving single cell counting, non-adherent cells are plated at low density (3–5% confluence) and treated with drug (2.5 μM) or vehicle (0.1% DMSO). Cells are diluted into trypan blue daily and viable cells counted using a hemocytometer<sup>[1]</sup>. **Animal Administration:** PP121 is prepared in 10% 1-methyl-2-pyrrolidinone and 90% PEG 300) group<sup>[2]</sup>.<sup>[2]</sup> Mouse: Eca-109 cells are injected into the axillary regions of nude mice (5×10<sup>6</sup> cells/mouse). When the tumor volumes reach around 200 mm<sup>3</sup>, the mice are randomly separated to three groups: Untreated control, PP121 (30 mg/kg) and vehicle (10% 1-methyl-2-pyrrolidinone and 90% PEG 300) group. Tumor volumes and the mice body weights are measured every 10 d<sup>[2]</sup>.

### References:

[1]. Apse B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol, 2008, 4(11), 691-699.

[2]. Peng Y, et al. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121. Biochem Biophys Res Commun. 2015 Sep 11;465(1):137-44.

**CAIndexNames:**

1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-

**SMILES:**

NC1=C2C(C3=CC4=C(N=C3)NC=C4)=NN(C2=NC=N1)C5CCCC5

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848

Fax: 888-484-5008

E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA